Literature DB >> 23569218

DNA microarray and miRNA analyses reinforce the classification of follicular thyroid tumors.

Caroline Jacques1, Delphine Guillotin, Jean-Fred Fontaine, Brigitte Franc, Delphine Mirebeau-Prunier, Audrey Fleury, Yves Malthiery, Frédérique Savagner.   

Abstract

CONTEXT: Focusing on mitochondrial function and thyroid tumorigenesis, we used an integrative approach to identify relevant biomarkers for borderline thyroid lesions.
DESIGN: Using cDNA and microRNA (miRNA) microarrays and quantitative RT-PCR analysis (qPCR), we explored samples of various types of thyroid tumors including 25 benign follicular adenomas represented by macrofollicular variants of thyroid adenomas, 38 oncocytic variants of follicular thyroid tumors, 19 papillary thyroid carcinomas, and 10 tumors of uncertain malignant potential, together with 53 normal thyroid tissue samples.
RESULTS: Our transcriptomic analysis, which highlighted discrepancies between controls and tumor tissues, as well as between various tumor types, led to the identification of 13 genes, allowing discrimination between the thyroid adenomas, oncocytic variants of follicular thyroid tumors, and papillary thyroid carcinomas, whereas the tumors of uncertain malignant potential were found to overlap these classes. Five of these genes (TP53, HOXA9, RUNX1, MYD88, and CITED1), with a differential expression confirmed by qPCR analysis, are implicated in tumorigenesis, 4 in mitochondrial metabolism (MRPL14, MRPS2, MRPS28, and COX6A1), and 2 in thyroid metabolic pathways (CaMKIINalpha and TPO). The global miRNA analysis revealed 62 differential miRNAs, the expression level for 10 of these being confirmed by qPCR. The differential expression of the miRNAs was in accordance with the modulation of gene expression and the ontologies revealed by our transcriptomic analysis.
CONCLUSIONS: These findings reinforce the classification of follicular thyroid tumors established by the World Health Organization, and our technique offers a novel molecular approach to refine the classification of thyroid tumors of uncertain malignant potential.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23569218     DOI: 10.1210/jc.2012-4006

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

Review 1.  Genome-wide analysis of microRNA and mRNA expression signatures in cancer.

Authors:  Ming-hui Li; Sheng-bo Fu; Hua-sheng Xiao
Journal:  Acta Pharmacol Sin       Date:  2015-08-24       Impact factor: 6.150

Review 2.  Noncoding RNAs in endocrine malignancy.

Authors:  Jessica Kentwell; Justin S Gundara; Stan B Sidhu
Journal:  Oncologist       Date:  2014-04-09

3.  MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells.

Authors:  Gillian Browne; Julie A Dragon; Deli Hong; Terri L Messier; Jonathan A R Gordon; Nicholas H Farina; Joseph R Boyd; Jennifer J VanOudenhove; Andrew W Perez; Sayyed K Zaidi; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Tumour Biol       Date:  2016-01-09

4.  Epigenetic regulation of thyroid hormone receptor beta in renal cancer.

Authors:  Anna Wojcicka; Agnieszka Piekielko-Witkowska; Hanna Kedzierska; Beata Rybicka; Piotr Poplawski; Joanna Boguslawska; Adam Master; Alicja Nauman
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

Review 5.  miRNA expression and function in thyroid carcinomas: a comparative and critical analysis and a model for other cancers.

Authors:  Manuel Saiselet; Jaime M Pita; Alice Augenlicht; Geneviève Dom; Maxime Tarabichi; Danai Fimereli; Jacques E Dumont; Vincent Detours; Carine Maenhaut
Journal:  Oncotarget       Date:  2016-08-09

6.  Transcriptional orchestration of mitochondrial homeostasis in a cellular model of PGC-1-related coactivator-dependent thyroid tumor.

Authors:  Solenne Dumont; Soazig Le Pennec; Audrey Donnart; Raluca Teusan; Marja Steenman; Catherine Chevalier; Rémi Houlgatte; Frédérique Savagner
Journal:  Oncotarget       Date:  2018-03-23

7.  Clinical Routine TERT Promoter Mutational Screening of Follicular Thyroid Tumors of Uncertain Malignant Potential (FT-UMPs): A Useful Predictor of Metastatic Disease.

Authors:  Martin Hysek; Johan O Paulsson; Kenbugul Jatta; Ivan Shabo; Adam Stenman; Anders Höög; Catharina Larsson; Jan Zedenius; Carl Christofer Juhlin
Journal:  Cancers (Basel)       Date:  2019-09-26       Impact factor: 6.639

8.  Oncogenic and tumor suppressor function of MEIS and associated factors.

Authors:  Birkan Gİrgİn; Medine KaradaĞ-Alpaslan; Fatih KocabaŞ
Journal:  Turk J Biol       Date:  2020-12-14

9.  TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.

Authors:  Miguel Melo; Adriana Gaspar da Rocha; João Vinagre; Rui Batista; Joana Peixoto; Catarina Tavares; Ricardo Celestino; Ana Almeida; Catarina Salgado; Catarina Eloy; Patrícia Castro; Hugo Prazeres; Jorge Lima; Teresina Amaro; Cláudia Lobo; Maria João Martins; Margarida Moura; Branca Cavaco; Valeriano Leite; José Manuel Cameselle-Teijeiro; Francisco Carrilho; Manuela Carvalheiro; Valdemar Máximo; Manuel Sobrinho-Simões; Paula Soares
Journal:  J Clin Endocrinol Metab       Date:  2014-01-29       Impact factor: 5.958

Review 10.  Candidate microRNAs as biomarkers of thyroid carcinoma: a systematic review, meta-analysis, and experimental validation.

Authors:  Yiren Hu; Hui Wang; Ende Chen; Zhifeng Xu; Bi Chen; Guowen Lu
Journal:  Cancer Med       Date:  2016-07-27       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.